CSF2 and COVID-19: On the other hand, blocking the GM-CSF receptor with mavrilimumab in cases of severe lung damage due to late-stage COVID-19 was suggested to reduce inflammation and control lung injury (197, 198), highlighting the dual role of the GM-CSF signaling pathway in tailoring macrophage polarization within disease progression.